Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 633-633

  Denning, David W ^a,b   Ghnan, Nesrin ^a   Kwizera, Richard ^a   Osmanov, Ali ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

A. fumigatus; Fungicidal; Paediatrics

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MONITORING; HUMAN; IN VITRO STUDY; LETTER; METABOLIC RATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; TOXICITY; ANIMAL; DRUG EFFECTS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HUMANS; VORICONAZOLE;

EID: 84922471089     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku330     Document Type: Letter

References (4)

1. Siopi M, Mavridou E, Mouton JW et al. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother 2014; 69: 1611-9.
2. 2 production: dependence on exposure time and drug concentration. J Antimicrob Chemother 2004; 54: 940-3.
3. Levêque D, Nivoix Y, Jehl F et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274-84.
4. Rex JH, Eisenstein BI, Alder J et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13: 269-75.